CTOs on the Move

Proteus Digital Health

www.proteus.com

 
As a company, we believe in digital health for everyone everywhere. We have created a new category of therapeutic product – the digital health feedback system – to allow people of all ages and cultures to power their own health, taking better care of themselves and each other. We see two trends: First, there are more people with mobile phones than there are with access to clean, running water. Second, chronic, often lifestyle-related diseases like diabetes are the world’s biggest healthcare problem, and our health systems can’t cope because they are optimized to treat the acute conditions prevalent decades ago. Our vision ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.proteus.com
  • 2600 Bridge Parkway Suite 101
    Redwood City, CA USA 94065
  • Phone: 650.632.4031

Executives

Name Title Contact Details

Funding

Proteus Digital Health raised $333.75M on 04/15/2016

Similar Companies

Med-Response Inc

Med-Response Inc is a Bluefield, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CleanCare Healthcare Division

CleanCare Healthcare Division is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wellframe

Wellframe helps healthcare organizations support people beyond the four walls of care delivery. We provide care transformation services, a patented engagement platform, clinical programs that support the clinical and social determinants of health, and rigorous measurement.

Elevate ENT Partners

ELEVATE ENT Partners is a practice management support organization that provides private ear, nose, and throat (ENT) practices with the business support, capital, and resources they need to provide focused, quality care to their patients, grow their pr...

Geron

We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.